Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues

Placenta. 2021 Jun:109:28-31. doi: 10.1016/j.placenta.2021.04.007. Epub 2021 Apr 16.

Abstract

Preeclampsia is a serious pregnancy complication associated with elevated antiangiogenic markers and endothelial dysfunction. Recently nicotinamide (vitamin B3) was shown to reduce high blood pressure and proteinuria in mice models of the disease. Using primary human pregnancy tissue we show nicotinamide did not change antiangiogenic factor secretion including soluble fms-like tyrosine kinase 1 or soluble endoglin from primary cytotrophoblasts and placental explants. Furthermore, it did not reverse markers of endothelial dysfunction. Therefore, we did not demonstrate an effect of nicotinamide on reducing markers of preeclampsia from primary human placental tissues and vascular cells.

Keywords: Nicotinamide; Placenta; Preeclampsia; Soluble endoglin; sFlt-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / metabolism*
  • Blood Vessels / drug effects
  • Blood Vessels / metabolism
  • Cells, Cultured
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiopathology
  • Female
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Niacinamide / pharmacology*
  • Placenta / blood supply
  • Placenta / drug effects*
  • Placenta / metabolism
  • Pregnancy
  • Primary Cell Culture

Substances

  • Angiogenesis Inhibitors
  • Niacinamide